Clinical Trial

Human CD19-CD22 Targeted T Cells Injection for Refractory/Relapsed Central Nervous System Leukemia/Lymphoma Patients

Active, Not Recruiting Early Phase 1
View on ClinicalTrials.gov →
Summary
This study is a open-label, dose-escalation trial to explore the safety, tolerability and pharmacokinetic/pharmacodynamics characteristics of Human CD19-CD22 Targeted T Cells by intravenous and intrathecal administration, and to preliminarily observe the efficacy of the trial drug in patients with central nervous system involvement of refractory/relapsed B cell malignancies.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2022-12-13; most recent amendment 2026-06-02.
Status change: Recruiting → Active, Not Recruiting 2026-06-02
Trial Details
NCT Number NCT05651178
Lead Sponsor Hrain Biotechnology Co., Ltd.
Collaborators: Second Affiliated Hospital of Nanchang University
Conditions Central Nervous System Lymphoma
Enrollment 10 participants
Start Date 2022-08-12
Primary Completion 2024-11-30 (estimated)
Study Completion 2027-05-31 (estimated)
Updated on ClinicalTrials.gov 2026-06-04